GlassScriptPhysician profile
Daniel G Wilson
NPI 1831160332
$1,326.75
in general payments reported to CMS, 2019-2025
21 companies · $84.21 in 2025
The $84.21 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $628 · 2022: $50.60 · 2023: $235 · 2024: $330 · 2025: $84.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $238.66 | 2021-2024 | Intellis Adaptivestim |
| Abbvie INC. | $218.82 | 2021-2024 | |
| Boston Scientific Corporation | $164.10 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $97.95 | 2021 | |
| Abbott Laboratories | $88.56 | 2024-2025 | Ensite, Cardiomems, Viewmate |
| Lundbeck LLC | $75.06 | 2023-2024 | Vyepti |
| Chiesi USA, INC. | $60.52 | 2021-2023 | Cleviprex, Kengreal |
| Nalu Medical, INC. | $59.37 | 2021-2024 | Nalu Neurostimulation System |
| Alnylam Pharmaceuticals INC. | $41.06 | 2021 | |
| Averitas Pharma INC. | $36.10 | 2025 | Qutenza |
| Ferring Pharmaceuticals INC. | $34.74 | 2023 | Euflexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.14 | 2021 | |
| Valinor Pharma, LLC | $30.53 | 2024 | Movantik |
| Bioventus LLC | $24.40 | 2024 | Durolane |
| Lilly USA, LLC | $20.80 | 2023 | Emgality, Reyvow |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $19.27 | 2024 | Licart, Tirosint |
| Forte Bio-Pharma LLC | $18.72 | 2024 | Prolate, Nalocet |
| Grt US Holding, INC. | $17.53 | 2021 | |
| Redhill Biopharma INC. | $16.68 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.99 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.75 | 2023 | Lyvispah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.